Calcific aortic stenosis: Another face of atherosclerosis?
Gian M. Novaro, MD
Department of Cardiovascular Medicine, The Cleveland Clinic, Weston, Florida
Brian P. Griffin, MD
Department of Cardiovascular Medicine, The Cleveland Clinic
Address: Brian P. Griffin, MD, Section of Cardiovascular Imaging, F15, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44122; e-mail: email@example.com
Dr. Novaro has indicated that he has received grant or research support from Pfizer Inc.
Dr. Griffin has indicated that he is on the speakers' bureau of the Merck corporation and has received grant or research support from Pfizer Inc.
This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.
ABSTRACTCalcific aortic stenosis is not the result of decades of wear and tear alone. Rather, it is being increasingly recognized as an inflammatory, atheromatous, and potentially modifiable disease. Exciting new research suggests that medical therapies may soon be available to retard its progression and reduce the need for surgery.